Latest Schedule 13G passive stakes

Polar Asset Management Partners Inc. has disclosed beneficial ownership of 5.6% of Blaize Holdings, Inc. common stock, acquiring 9,375,000 shares.

Polar Asset Management Partners Inc. has disclosed beneficial ownership of 1,150 Class A Ordinary Shares, representing 5.2% of the class, in Collective Acquisition Corp. II.

Polar Asset Management Partners Inc. has disclosed beneficial ownership of 8.9% of Disciplined Growth Acquisition Corp's Class A Ordinary Shares as of June 30, 2026.

Polar Asset Management Partners Inc. has disclosed beneficial ownership of 5.0% of Harvard Ave Acquisition Corp.'s Class A Ordinary Shares, signaling a notable investment position.

Polar Asset Management Partners Inc. has disclosed a beneficial ownership of 1,000,000 Class A Ordinary Shares, representing 6.3% of the class, in Iron Dome Acquisition I Corp.

Polar Asset Management Partners Inc. has disclosed beneficial ownership of 5.0% of Oceanhawk Acquisition Corp.'s Class A Ordinary Shares, totaling 950,000 shares.

Polar Asset Management Partners Inc. has disclosed beneficial ownership of 1,200,000 Class A Ordinary Shares, representing 5.2% of the class, in Wilco 63 Corp.

Polar Asset Management Partners Inc. has disclosed beneficial ownership of 7.0% of Incannex Healthcare Inc.'s common stock, acquiring 900,000 shares via warrants.

Polar Asset Management Partners Inc. has disclosed beneficial ownership of 1,965,000 Class A Ordinary Shares, representing 8.3% of the class, in GSR V Acquisition Corp.

Hivemind Capital Partners, LLC and its affiliates have disclosed a beneficial ownership stake of 9.99% in Upexi, Inc., primarily through common stock, pre-funded warrants, and a convertible note.

Hivemind Capital Partners, along with affiliated entities, has reported beneficial ownership of 6,841,923 shares of Upexi, Inc. common stock, representing 9.99% of the outstanding shares.

ADAR1 Capital Management, LLC and Daniel Schneeberger have filed a joint Schedule 13G statement regarding their beneficial ownership of NextCure, Inc. common stock.

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 8.8% of Yarrow Bioscience, Inc. common stock as of June 30, 2026.

ADAR1 Capital Management, LLC and its manager Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 4,500,000 shares, representing 5.3% of Rein Therapeutics, Inc.'s common stock as of June 30, 2026.

Merus Global Investments, LLC has filed an amendment to its Schedule 13G, reporting a complete divestment of its holdings in General Fusion Group Ltd.

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 8.4% of Research Alliance Corporation III's Class A Ordinary Shares.

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 8.9% of Pliant Therapeutics, Inc. common stock as of June 30, 2026.

ADAR1 Capital Management, LLC and its manager Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 417,724 Ordinary Shares, representing 5.4% of the outstanding shares of JATT II Acquisition Corp.

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 5.8% of Editas Medicine, Inc. common stock as of June 30, 2026.

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 7.0% of Cyclerion Therapeutics, Inc. common stock as of June 30, 2026.

ADAR1 Capital Management and Daniel Schneeberger have filed a joint Schedule 13G, reporting beneficial ownership of 8.8% of Boundless Bio, Inc. common stock as of June 30, 2026.

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, disclosing beneficial ownership of 9.6% of Amanat Acquisition Corp.'s Class A Ordinary Shares as of June 30, 2026.

CP BF Lending, LLC has filed a Schedule 13G, disclosing beneficial ownership of 1,079,713 shares of Banzai International's Class A common stock, representing 24.8% of the outstanding shares.

Ikarian Capital, LLC and Neil Shahrestani have filed a Schedule 13G, reporting beneficial ownership of 9.9% of CNS Pharmaceuticals, Inc. common stock.

Ikarian Capital, LLC and Neil Shahrestani have reported a beneficial ownership of 6.9% in Connect Biopharma Holdings Limited's ordinary shares.

Ikarian Capital, LLC and Neil Shahrestani have reported beneficial ownership of 9.0% of Quince Therapeutics, Inc. common stock as of June 30, 2026.

Ikarian Capital, LLC and Neil Shahrestani have jointly filed a Schedule 13G, reporting beneficial ownership of 9.5% of Traws Pharma, Inc.'s common stock, including shares issuable upon warrant exercise.

Ikarian Capital, LLC and Neil Shahrestani have filed a Schedule 13G, reporting beneficial ownership of 1,080,700 shares, representing 2.9% of Tenax Therapeutics, Inc.'s common stock.

Ikarian Capital, LLC and Neil Shahrestani have reported beneficial ownership of 4.2% of InMed Pharmaceuticals Inc. common shares, totaling 137,634 shares.

Ikarian Capital, LLC and Neil Shahrestani have reported a complete divestment of their holdings in Galera Therapeutics, Inc., indicating a significant shift in their investment strategy.